Neuroblastoma Drugs Market Size & Share, by Drug Type (Cisplatin, Etoposide, Topotecan, Doxorubicin); Mechanism Type (Antibiotics, Microtubule Inhibitors, Alkylating Agents); Treatment Type (Chemotherapy, Bone Marrow Transplantation, Retinoid Therapy, Immunotherapy, Surgery); Diagnosis Type (Imaging Test, Physical Test, Bone Marrow Sample Testing); End-user (Hospitals, Speciality Clinics, Homecare) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 2769
  • Published Date: Apr 20, 2023
  • Report Format: PDF, PPT

Companies Dominating the Neuroblastoma Drugs Landscape

top-features-companies
    • CELLECTAR BIOSCIENCES, INC. 
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • APEIRON Biologics AG
    • Pfizer Inc.
    • Eli Lilly and Company
    • AstraZeneca
    • Teva Pharmaceutical Industries Ltd.
    • Bristol-Myers Squibb Company
    • MacroGenics Inc.
    • Marsala Biotech Inc.
    • Johnson & Johnson Services, Inc.

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • Teva Pharmaceutical Industries Ltd. in Association with Global HOPE (Hematology Oncology Pediatric Excellence) donated over 566,000 doses of medicine, and helped with the training of over 5,600 healthcare professionals across Africa by providing required care, health services, and medical resources.

  • Eli Lilly and Company started research on genomic testing in cancer in order to find weaknesses in tumor makeup and to design more targeted treatment. Further, Lilly Oncology is working to spread the knowledge about genomic testing in cancer diagnosis and treatment.


Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 2769
  • Published Date: Apr 20, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increasing the practice of chemotherapy, and a high number of people with early diagnosis test awareness are the major factors driving the market growth.

The market size of neuroblastoma drugs is anticipated to attain a CAGR of 5% over the forecast period, i.e., 2023-2035.

Lack of awareness about disease occurrence and rising side effects of antibiotics are estimated to be the growth hindering factors for the market expansion.

The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are CELLECTAR BIOSCIENCES, INC., APEIRON Biologics AG, Pfizer Inc., Eli Lilly and Company, AstraZeneca, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company, MacroGenics Inc., Marsala Biotech Inc., Johnson & Johnson Services, Inc., and others.

The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by drug type, mechanism type, treatment type, diagnosis type, end user, and by region.

The chemotherapy segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying